About Stoke Therapeutics
Stoke Therapeutics is a company based in Bedford (United States) founded in 2014 by Adrian Krainer.. Stoke Therapeutics has raised $130.85 million across 3 funding rounds from investors including RTW Investments, RA Capital and Perceptive Advisors. The company has 128 employees as of December 31, 2024. Stoke Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Bedford, United States
- Employees 128 as on 31 Dec, 2024
- Founders Adrian Krainer
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Stoke Therapeutics, Inc.
-
Annual Revenue
$36.55 M316.34as on Dec 31, 2024
-
Net Profit
$-88.98 M15.01as on Dec 31, 2024
-
EBITDA
$-96.93 M11.92as on Dec 31, 2024
-
Total Equity Funding
$130.85 M (USD)
in 3 rounds
-
Latest Funding Round
$90 M (USD), Series B
Oct 23, 2018
-
Investors
RTW Investments
& 6 more
-
Employee Count
128
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Stoke Therapeutics
Stoke Therapeutics is a publicly listed company on the NASDAQ with ticker symbol STOK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
18 people
Legal and Compliance
5 people
Human Resources and Administration
4 people
Clinical Team
3 people
Software Development Team
3 people
Finance and Accounting
2 people
Product Management Team
2 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Stoke Therapeutics
Stoke Therapeutics has successfully raised a total of $130.85M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $90 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $90.0M
-
First Round
First Round
(21 Nov 2014)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2018 | Amount | Series B - Stoke Therapeutics | Valuation | RTW Investments | |
| Jan, 2018 | Amount | Series A - Stoke Therapeutics | Valuation | Apple Tree Partners |
|
| Nov, 2014 | Amount | Seed - Stoke Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Stoke Therapeutics
Stoke Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include RTW Investments, RA Capital and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Apple Tree Partners is engaged in life sciences venture capital.
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Stoke Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Stoke Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Stoke Therapeutics Comparisons
Competitors of Stoke Therapeutics
Stoke Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Stoke Therapeutics
Frequently Asked Questions about Stoke Therapeutics
When was Stoke Therapeutics founded?
Stoke Therapeutics was founded in 2014.
Where is Stoke Therapeutics located?
Stoke Therapeutics is headquartered in Bedford, United States.
Who is the current CEO of Stoke Therapeutics?
Edward M Kaye is the current CEO of Stoke Therapeutics.
Is Stoke Therapeutics a funded company?
Stoke Therapeutics is a funded company, having raised a total of $130.85M across 3 funding rounds to date. The company's 1st funding round was a Seed of $850K, raised on Nov 21, 2014.
How many employees does Stoke Therapeutics have?
As of Dec 31, 2024, the latest employee count at Stoke Therapeutics is 128.
What is the annual revenue of Stoke Therapeutics?
Annual revenue of Stoke Therapeutics is $36.55M as on Dec 31, 2024.
What does Stoke Therapeutics do?
Stoke Therapeutics was founded in 2014 and is headquartered in Bedford, United States. Antisense oligonucleotide therapeutics are developed by the company to address inherited diseases through modulation of RNA splicing. The proprietary Targeted Augmentation of Nuclear Gene Output platform is utilized to enhance gene expression in a precise manner. A pipeline of candidates is being advanced for conditions affecting the central nervous system, eye, liver, and blood disorders.
Who are the top competitors of Stoke Therapeutics?
Stoke Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Is Stoke Therapeutics publicly traded?
Yes, Stoke Therapeutics is publicly traded on NASDAQ under the ticker symbol STOK.
Who are Stoke Therapeutics's investors?
Stoke Therapeutics has 7 investors. Key investors include RTW Investments, RA Capital, Perceptive Advisors, Apple Tree Partners, and Acks.
What is Stoke Therapeutics's ticker symbol?
The ticker symbol of Stoke Therapeutics is STOK on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.